United Therapeutics initiated with "buy"

02/14/07 - Brean Murray, Carret & Co

NEW YORK, February 14 (newratings.com) - Analysts at Brean Murray initiate coverage of United Therapeutics Corp (UTHR) with a "buy" rating. The target price is set to $65.

In a research note published yesterday, the analysts mention that the company is likely to successfully develop and market the inhaled and oral formulations of its Remodulin drug going forward. The analysts expect the market share for United Therapeutics' Remodulin to continue to expand moving ahead. The company is expected to continue to generate robust revenues going forward, Brean Murray adds.